Immunohistochemical expression of CD10 antigen in uterine adenosarcoma

被引:23
作者
Amant, F
Steenkiste, E
Schurmans, K
Verbist, L
Abeler, VM
Tulunay, G
De Jonge, E
Massuger, L
Moerman, P
Vergote, I
机构
[1] Katholieke Univ Leuven Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, B-3000 Louvain, Belgium
[2] Katholieke Univ Leuven Hosp, Dept Pathol, Louvain, Belgium
[3] Norwegian Radium Hosp, Dept Pathol, Oslo, Norway
[4] SSK Ankara Matern & Womens Hosp, Dept Gynecol Oncol, Ankara, Turkey
[5] Ziekenhuis Oost Limburg, Dept Obstet & Gynecol, Genk, Belgium
[6] Univ Nijmegen St Radboud Hosp, Dept Obstet & Gynecol, NL-6500 HB Nijmegen, Netherlands
关键词
adenosarcoma; CD10; immunohistochemistry; stromal; uterus;
D O I
10.1111/j.1048-891X.2004.14610.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Uterine adenosarcoma (UAS) is microscopically characterized by a biphasic growth pattern. By definition, the epithelial component is benign, whereas the stromal component typically has the appearance of a low-grade sarcoma, usually an endometrial stromal sarcoma. CD10 acts by reducing cellular response to peptide hormones and is currently regarded as a specific marker for endometrial stromal tumors. In this international multicenter study, we further explored CD10 immunoreactivity in 30 UASs. We encountered CD10 positivity of the sarcomatous component in 18/20 (90%) of UASs, in five of eight (63%) of UASs with sarcomatous overgrowth as well as in both cases of recurrent UAS. The epithelial component stained negative in all cases. These findings suggest that CD10 can be used to differentiate UAS from cellular leiomyoma, or in case endometrial stromal cells exhibit muscle differentiation. Furthermore, CD10 positivity in recurrent UAS might guide the pathologist toward an endometrial stromal origin.
引用
收藏
页码:1118 / 1121
页数:4
相关论文
共 18 条